Abstract
Background: Lipoxygenases(LOXs) are a family of enzymes which catalyze the oxidation of unsaturated fatty acids.
Objective: To quantitatively disclose the relationship between activity and structure of a series of 12- LOX inhibitors.
Method: 3D-QSAR (three dimensions quantitative structure-activity relationship) studies based on COMFA(comparative molecular field analysis) and COMSIA(comparative molecular similarity indices analysis) and pharmacophore studies were performed.
Results: 3D-QSAR results show that both CoMFA and CoMSIA models yielded well statistical significance respectively, with q2=0.708, r2=0.983, F=162.3, SEE=0.090 in CoMFA model and q2=0.735, r2=0.981, F=130.5, SEE=0.095 in CoMSIA model, four derivatives as potential 12-LOX inhibitors with high predicted bioactivities has been designed. Additionally, pharmacophore results suggested different group on the core parts of 12-LOX inhibitor might enhance the bioactivities.
Keywords: 12-Lipoxygenase, 3D-QSAR, CoMFA, CoMSIA, pharmacophore, docking.
Letters in Drug Design & Discovery
Title:Combined 3D-QSAR, Pharmacophore and Docking Studies on Benzenesulfonamide Derivatives as Potent 12-Lipoxygenase Inhibitors
Volume: 14 Issue: 1
Author(s): Chunhong An, Mao Shu, Xiaoli Zai, Beina Zhang, Jing Li, Zichao Chang, Yong Hu and Zhihua Lin
Affiliation:
Keywords: 12-Lipoxygenase, 3D-QSAR, CoMFA, CoMSIA, pharmacophore, docking.
Abstract: Background: Lipoxygenases(LOXs) are a family of enzymes which catalyze the oxidation of unsaturated fatty acids.
Objective: To quantitatively disclose the relationship between activity and structure of a series of 12- LOX inhibitors.
Method: 3D-QSAR (three dimensions quantitative structure-activity relationship) studies based on COMFA(comparative molecular field analysis) and COMSIA(comparative molecular similarity indices analysis) and pharmacophore studies were performed.
Results: 3D-QSAR results show that both CoMFA and CoMSIA models yielded well statistical significance respectively, with q2=0.708, r2=0.983, F=162.3, SEE=0.090 in CoMFA model and q2=0.735, r2=0.981, F=130.5, SEE=0.095 in CoMSIA model, four derivatives as potential 12-LOX inhibitors with high predicted bioactivities has been designed. Additionally, pharmacophore results suggested different group on the core parts of 12-LOX inhibitor might enhance the bioactivities.
Export Options
About this article
Cite this article as:
An Chunhong, Shu Mao, Zai Xiaoli, Zhang Beina, Li Jing, Chang Zichao, Hu Yong and Lin Zhihua, Combined 3D-QSAR, Pharmacophore and Docking Studies on Benzenesulfonamide Derivatives as Potent 12-Lipoxygenase Inhibitors, Letters in Drug Design & Discovery 2017; 14 (1) . https://dx.doi.org/10.2174/1570180813666160930100456
DOI https://dx.doi.org/10.2174/1570180813666160930100456 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Enteric Neurons and Plexitis for the Management of Inflammatory Bowel Disease
Current Drug Targets The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Synthesis and in vitro Cytotoxicity Studies of Certain Novel Heterocycles Derived from Bis 1, 2, 4-Triazoles and their DNA Damage Studies
Medicinal Chemistry Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance
Current Medicinal Chemistry The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets Soy Phytoestrogens and Breast Cancer Chemoprevention: Molecular Mechanisms
Current Nutrition & Food Science The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Current Protein & Peptide Science Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics Rapid Screening of Different Types of Antitumor Compound Groups from Traditional Chinese Medicine by Hollow Fiber Cell Fishing with High Performance Liquid Chromatography
Combinatorial Chemistry & High Throughput Screening Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase
Current Computer-Aided Drug Design Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry